相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study
Yaseen M. Arabi et al.
CLINICAL INFECTIOUS DISEASES (2020)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
Qiurong Ruan et al.
INTENSIVE CARE MEDICINE (2020)
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
Barnaby Edward Young et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
Dawei Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
Calvin J. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Clark D. Russell et al.
LANCET (2020)
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
Roujian Lu et al.
LANCET (2020)
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen et al.
LANCET (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Convalescent plasma as a potential therapy for COVID-19
Long Chen et al.
LANCET INFECTIOUS DISEASES (2020)
COVID-19: combining antiviral and anti-inflammatory treatments
Justin Stebbing et al.
LANCET INFECTIOUS DISEASES (2020)
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Guangdi Li et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Defining the Epidemiology of Covid-19-Studies Needed
Marc Lipsitch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases
Tao Ai et al.
RADIOLOGY (2020)
The COVID-19 epidemic
Thirumalaisamy P. Velavan et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2020)
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Timothy P. Sheahan et al.
NATURE COMMUNICATIONS (2020)
Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks
Hossam M. Ashour et al.
PATHOGENS (2020)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Xueting Yao et al.
CLINICAL INFECTIOUS DISEASES (2020)
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
Xiaobo Yang et al.
Lancet Respiratory Medicine (2020)
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Zhe Xu et al.
LANCET RESPIRATORY MEDICINE (2020)
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Jianjun Gao et al.
BIOSCIENCE TRENDS (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Implications of COVID-19 for patients with pre-existing digestive diseases
Ren Mao et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Liying Dong et al.
DRUG DISCOVERIES AND THERAPEUTICS (2020)
2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed Tomography Findings
Jiangping Wei et al.
KOREAN JOURNAL OF RADIOLOGY (2020)
Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness
Ana E. Gamino-Arroyo et al.
CLINICAL INFECTIOUS DISEASES (2019)
Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge
Michael K. Lo et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Egor P. Tchesnokov et al.
VIRUSES-BASEL (2019)
Therapeutic strategies to target the Ebola virus life cycle
Thomas Hoenen et al.
NATURE REVIEWS MICROBIOLOGY (2019)
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Sabue Mulangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
Yaseen M. Arabi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Maria L. Agostini et al.
MBIO (2018)
Middle East Respiratory Syndrome
Yaseen M. Arabi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials
Vincent Madelain et al.
CLINICAL PHARMACOKINETICS (2016)
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren et al.
NATURE (2016)
A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs
Jianzhong Cao et al.
ANTIVIRAL RESEARCH (2015)
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
Jasper Fuk-Woo Chan et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Jean-Francois Rossignol
ANTIVIRAL RESEARCH (2014)
Arbidol as a broad-spectrum antiviral: An update
Julie Blaising et al.
ANTIVIRAL RESEARCH (2014)
Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone
Anil Pareek et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial
Jason Haffizulla et al.
LANCET INFECTIOUS DISEASES (2014)
Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
Ali S. Omrani et al.
LANCET INFECTIOUS DISEASES (2014)
Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment
Susanna K. P. Lau et al.
JOURNAL OF GENERAL VIROLOGY (2013)
Inhibition of novel β coronavirus replication by a combination of interferon- α2b and ribavirin
Darryl Falzarano et al.
SCIENTIFIC REPORTS (2013)
Administration of antiretroviral medication via enteral tubes
Emily S. Prohaska et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2012)
Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides
Aesop Cho et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
Mark S. Sulkowski et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin
Eva Vets et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
Study of the In Vitro Activities of Rifaximin and Comparator Agents against 536 Anaerobic Intestinal Bacteria from the Perspective of Potential Utility in Pathology Involving Bowel Flora
S. M. Finegold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level
Jean Francois Rossignol et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Human immunopathogenesis of severe acute respiratory syndrome (SARS)
Mark J. Cameron et al.
VIRUS RESEARCH (2008)
Up-regulation of IL-6 and TNF-α induced by SARS-coronavirus spike protein in murine macrophages via NF-κB pathway
Wei Wang et al.
VIRUS RESEARCH (2007)
Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment?
Thomas C. Luke et al.
ANNALS OF INTERNAL MEDICINE (2006)
SARS: Systematic review of treatment effects
Lauren J. Stockman et al.
PLOS MEDICINE (2006)
Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
J Paragas et al.
ANTIVIRAL RESEARCH (2005)
Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
B Morgenstern et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Martin J. Vincent et al.
VIROLOGY JOURNAL (2005)
Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs
ELC Tan et al.
EMERGING INFECTIOUS DISEASES (2004)
Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
BL Haagmans et al.
NATURE MEDICINE (2004)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
CM Chu et al.
THORAX (2004)
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
F Chen et al.
JOURNAL OF CLINICAL VIROLOGY (2004)
Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients
YOY Soo et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
N Yamamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
E Keyaerts et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada
SR Knowles et al.
CLINICAL INFECTIOUS DISEASES (2003)
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
CM Booth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
A cluster of cases of severe acute respiratory syndrome in Hong Kong
KW Tsang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Side effects of therapy for chronic hepatitis C
MW Russo et al.
GASTROENTEROLOGY (2003)
Lopinavir/ritonavir - A review of its use in the management of HIV infection
RS Cvetkovic et al.
DRUGS (2003)
Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial
B Amadi et al.
LANCET (2002)
Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C
CH Chang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Ribavirin's antiviral mechanism of action: lethal mutagenesis?
S Crotty et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2002)
The anti-HIV-1 activity of chloroquine
A Savarino et al.
JOURNAL OF CLINICAL VIROLOGY (2001)
Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease
Y Khaliq et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
分享论文
